TRIB (Trinity Biotech) Long-Term Debt: $16.33 Mil (As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
28 GF Score
Price $0.38
GF Value $0.74
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech Long-Term Debt?

Trinity Biotech TRIB +0.90% 28 Long-Term Debt is $16.33 Mil as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 28/100 and a GF Value™ of $0.74 (Possible Value Trap). The stock has 7 warning signs investors should review.

Trinity Biotech's Long-Term Debt for the quarter that ended in Dec. 2025 was $16.33 Mil.

Trinity Biotech's quarterly Long-Term Debt increased from Dec. 2024 ($87.79 Mil) to Jun. 2025 ($99.50 Mil) but then declined from Jun. 2025 ($99.50 Mil) to Dec. 2025 ($16.33 Mil).

Trinity Biotech's annual Long-Term Debt increased from Dec. 2023 ($54.65 Mil) to Dec. 2024 ($87.79 Mil) but then declined from Dec. 2024 ($87.79 Mil) to Dec. 2025 ($16.33 Mil).

Trinity Biotech  (NAS:TRIB) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Trinity Biotech Long-Term Debt Related Terms

Trinity Biotech Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech Long-Term Debt Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 58.05 54.65 87.79 16.33

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 54.65 80.77 87.79 99.50 16.33
TRIB
28GF Score
Trinity Biotech PLC TRIB
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of $16.33 Mil mean?
Trinity Biotech (TRIB) has a Long-Term Debt of $16.33 Mil as of Dec. 2025.
Is Trinity Biotech's Long-Term Debt too high?
Trinity Biotech's current Long-Term Debt is $16.33 Mil. Overall, Trinity Biotech has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's Long-Term Debt compare to AIDX and NVNO?
Trinity Biotech's Long-Term Debt of $16.33 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Medical Devices & Instruments company?
A good Long-Term Debt depends on the Medical Devices & Instruments industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Trinity Biotech's current Long-Term Debt is $16.33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.74, compared to a current price of $0.38 — trading 48.7% below its estimated fair value. The current Long-Term Debt is $16.33 Mil. Trinity Biotech's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current Long-Term Debt is $16.33 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.38 is trading 48.7% below its estimated GF Value™ of $0.74. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • Long-Term Debt: $16.33 Mil
  • GF Value™: $0.74 vs. price of $0.38 (48.7% below fair value)
  • GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
28GF Score

Get the complete analysis for TRIB

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.38
Price
$0.74
GF Value